Alzheimer’s has long been considered irreversible, but new research challenges that assumption. Scientists discovered that severe drops in the brain’s energy supply help drive the disease—and ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

To connoisseurs of fine cinematic car chases, there's nothing better than seeing a hot rod roaring down the street in reverse to escape certain doom. What's better? Doing it yourself, but let's be ...

YieldMax Ultra Option Income Strategy ETF has seen its NAV collapse 79% since inception. Its total return is now negative. ULTY's strategy of holding volatile stocks and writing call options has ...

Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results. Will dialysis and organ transplants become a thing of the past? A healthy ...

Named after a pair of psychologists who described it in a classic 1999 paper, the Dunning-Kruger effect describes a common dynamic most of us have observed in everyday life. People who know the least ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

When people think about automation, the focus is almost always on what it takes away. They see it as machines taking over tasks, making jobs disappear. But there’s another side to the story that’s ...